Empagliflozin in the treatment of type 2 diabetes: Evidence to date

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5793-5803

  Shubrook, Jay H ^a   Bokaie, Babak Baradar ^b   Adkins, Sarah E ^c  

^a Touro University California   (United States)

^b OHIO UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Empagliflozin; Glucosuria; Kidneys; SGLT 2 inhibitors; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ALBUMIN; CANAGLIFLOZIN; CHOLESTEROL; CREATININE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ADD ON THERAPY; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HEADACHE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DYSFUNCTION; KIDNEY TUBULE ABSORPTION; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MEDICAL RESEARCH; MICROALBUMINURIA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLLAKISURIA; RENAL PROTECTION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED STATES; URINARY TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; DRUG EFFECTS; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84946601405     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S69926     Document Type: Review

References (58)

1. International Diabetes Federation. Diabetes Atlas. Available from: http://www.idf.org/diabetesatlas. Accessed January 3, 2015
2. World Health Organization. Facts and figures about diabetes. Available from: http://www.who.int/diabetes/facts/en/. Accessed January 3, 2015
3. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58:773–795
4. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14
5. Gerich JE. Role of the kidneys in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabetic Med. 2010;27(2):136–142
6. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78–89
7. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380
8. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794
9. Tabatabai NM, Sharma M, Blumenthal SS, et al. Enhanced expressions of sodium-glucose co-transporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract. 2009;83:e27–e30
10. Vallon V, Rose M, Gerasimova M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol. 2013;304:F156–F167
11. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes. 2005;54:3227–3234
12. Mering J. Ueber kuenstlichen diabetes [Through artificial diabetes]. Centralbl Med Wiss. 1886; xxxii:531
13. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–38
14. Abdul-Ghani MA, Norton L, Defronzo RA. Role of the sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531
15. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 19(2):34–42
16. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003; 14(11):2873–2882
17. Turk E, Zabel B, Munidos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354–356
18. Liang Y, Arakawa K, Ueta K, et al. Effect of canagliflozin on renal threshold, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7(2):e30555. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280264/pdf/pone.0030555.pdf. Accessed September 10, 2015
19. Whaley JM, Tirmenstein M, Reilly TP, et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2012;5:135–148
20. www.FDA.gov [homepage on the Internet]. FDA News Release. FDA Approves Invokana to treat Type 2 diabetes. Released March 29, 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed October 3, 2015
21. U.S. Department of Health and Human Services, Food and Drug Administration. FDA approves Jardiance to treat type 2 diabetes [FDA News Release]. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2014 [August 1]s. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm407637.htm. Accessed April 12, 2015
22. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90
23. ® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014
24. Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012;14(1):94–96
25. Seman L, Macha S, Nehmlz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152–161
26. Sarashina A, Koiwai K, Seman L, et al. Safety, tolerability pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3): 213–219
27. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 week’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613–621
28. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013; 4(2): 331–345
29. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized placebo controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–728
30. Macha S, Rose P, Mattheus M, et al. Pharmacokinetic, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT 2) inhibitor in subjects with renal impairment. Diabetes Obes Metab. 2014;16(3):215–222
31. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a soidium glucose co-transporter 2 (SGLT2) inhibitor in patients with hepatic impairment. Diabetes Obes Metab. 2014;2:118–123
32. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Ca. 2013;36:2154–2161
33. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509–514
34. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217–2224
35. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208–219
36. Roden M, Weng J, Merker L, et al. Empagliflozin monotherapy in drug naïve patients with type 2 diabetes (EMPA-REG-EXTEND MONO) [poster 264-OR]. Poster presented at: ADA Scientific Sessions 2014, San Francisco, CA, USA
37. Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as an add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396–3404
38. Häring HU, Merker L, Seewaldt-Becker E, et al; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37(6):1650–1659
39. Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(9):691–700
40. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improved glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2013;16(2):147–158
41. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–1823
42. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62(2):170–180. doi:10.1002/acr.20065
43. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014; 2(5):369–384
44. Vasilakou D, Karaglannis T, Athanasladou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274
45. Toto RD, Wanner C, Gerich J, et al. No overall increase in volume depletion events with empagliflozin (EMPA) in a pooled analysis of more than 11,000 patients with type 2 diabetes (T2DM). J Am Soc Nephrol. 2013;24(Suppl):Abstract SA-PO373
46. Bonner C, Kerr-Conte I, Gmys V, Quealat G, Moerman E, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;121:512–517
47. ® [package insert]. Ridgefield, CT. Boehringer Ingleheim Pharmaceuticals, Inc; January 2015
48. Lewin A, DeFronzo R, Patel S, et al. Initial combination therapy with empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402
49. DeFronzo R, Lewin A, Patel S, et al. Fixed dose combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393
50. Cherney DZ, Eynatten MV, Lund SS, et al. Sodium glucose cotransporter 2 (SGLT2) inhibition with empagliflozin reduces microalbuminuria in patients with type 2 diabetes [Poster 1125-P]. Poster presented at: ADA 74th Scientific Sessions 2014, San Francisco, CA, USA
51. Perkins BA, Cheney DZ, Patridge H, et al. Sodium glucose co-transporter 2 inhibitor and glycemic control in type 1 diabetes: results of an 8 week open label proof of concept trial. Diabetes Care. 2014;37(5): 1480–1483
52. Skrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014; 57(12):2599–2602
53. Lamos E, Younk L, Davis S. Emapgliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014;23:875–882
54. Cheney DZ, Perkins BA, Soleymanlou Y, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28
55. Cheney DZ, Perkins BA, Soleymanlou Y, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–597
56. AACE/ACE Comprehensive Diabetes Management Algorithm 2015 and AACE/ACE Diabetes Clinical Practice Guidelines. Available from: https://www.aace.com/publications/algorithm. Accessed April 4, 2015
57. McGill J. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63
58. Miller E, Shubrook JH. Role of the kidneys and sodium glucose co-transporter 2 (sglt2) inhibitors in the treatment of type 2 diabetes mellitus. Osteopathic Family Physician. 2015;1(5):10–30.